Dirk J Van Veldhuisen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7952635/publications.pdf

Version: 2024-02-01

341	23,329	9756	10708
papers	citations	73 h-index	138 g-index

348	348	348	22489
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population. Circulation, 2002, 106, 1777-1782.	1.6	1,395
2	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal, 2015, 36, 657-668.	1.0	902
3	Increased Central Venous Pressure Is Associated With Impaired Renal Function and Mortality in a Broad Spectrum of Patients With Cardiovascular Disease. Journal of the American College of Cardiology, 2009, 53, 582-588.	1.2	796
4	Iron deficiency in chronic heart failure: An international pooled analysis. American Heart Journal, 2013, 165, 575-582.e3.	1.2	532
5	Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. European Heart Journal, 2013, 34, 1424-1431.	1.0	451
6	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	2.9	434
7	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal, 2018, 39, 26-35.	1.0	426
8	Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2009, 53, 2150-2158.	1.2	405
9	Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure. Circulation, 2011, 124, 1719-1726.	1.6	392
10	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of reninâ€“angiotensinâ€“aldosterone inhibitors. European Heart Journal, 2020, 41, 1810-1817.	1.0	381
11	B-Type Natriuretic Peptide and Prognosis in Heart Failure Patients With Preserved and Reduced Ejection Fraction. Journal of the American College of Cardiology, 2013, 61, 1498-1506.	1.2	352
12	Effects of ferric carboxymaltose on hospitalisations and mortality rates in ironâ€deficient heart failure patients: an individual patient data metaâ€analysis. European Journal of Heart Failure, 2018, 20, 125-133.	2.9	317
13	Trans-ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and implicates a role for DNA methylation. Nature Genetics, 2015, 47, 1282-1293.	9.4	294
14	Heart Failure With Preserved EjectionÂFraction andÂAtrial Fibrillation. Journal of the American College of Cardiology, 2016, 68, 2217-2228.	1.2	292
15	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation, 2017, 136, 1374-1383.	1.6	289
16	Vagus Nerve Stimulation for the Treatment of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 149-158.	1.2	283
17	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. Nature Genetics, 2014, 46, 826-836.	9.4	281
18	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. European Heart Journal, 2014, 35, 1284-1293.	1.0	276

#	Article	IF	Citations
19	Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. European Heart Journal, 2015, 36, 2565-2573.	1.0	274
20	Heart failure with preserved ejection fraction: from mechanisms to therapies. European Heart Journal, 2018, 39, 2780-2792.	1.0	250
21	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351.	1.6	244
22	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	2.9	239
23	Angiotensin Receptor Neprilysin InhibitionÂin Heart Failure With PreservedÂEjection Fraction. JACC: Heart Failure, 2017, 5, 471-482.	1.9	238
24	Sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin improves cardiac function in nonâ€diabetic rats with left ventricular dysfunction after myocardial infarction. European Journal of Heart Failure, 2019, 21, 862-873.	2.9	236
25	Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation, 2018, 138, 678-691.	1.6	229
26	Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. European Journal of Heart Failure, 2018, 20, 910-919.	2.9	225
27	Iron deficiency and cardiovascular disease. Nature Reviews Cardiology, 2015, 12, 659-669.	6.1	220
28	Prospective validation and assessment of cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart, 2014, 100, 1373-1381.	1.2	206
29	Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. European Heart Journal, 2018, 39, 2987-2996.	1.0	203
30	Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and metaâ€analysis. European Journal of Heart Failure, 2016, 18, 1472-1487.	2.9	200
31	Identifying Pathophysiological Mechanisms in Heart Failure WithÂReduced Versus Preserved EjectionÂFraction. Journal of the American College of Cardiology, 2018, 72, 1081-1090.	1.2	199
32	Heart Rate and Rhythm and the BenefitÂofÂBeta-Blockers in PatientsÂWithÂHeart Failure. Journal of the American College of Cardiology, 2017, 69, 2885-2896.	1.2	198
33	Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. European Heart Journal, 2007, 28, 2208-2216.	1.0	184
34	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. European Journal of Heart Failure, 2017, 19, 627-634.	2.9	183
35	Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the RAte Control versus Electrical cardioversion (RACE) study. American Heart Journal, 2005, 149, 1106-1111.	1.2	177
36	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nature Reviews Cardiology, 2011, 8, 485-493.	6.1	175

#	Article	IF	Citations
37	Epicardial fat in heart failure patients with midâ€range and preserved ejection fraction. European Journal of Heart Failure, 2018, 20, 1559-1566.	2.9	173
38	The clinical significance of interleukinâ€6 in heart failure: results from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 965-973.	2.9	172
39	Signature of circulating <scp>microRNAs</scp> in patients with acute heart failure. European Journal of Heart Failure, 2016, 18, 414-423.	2.9	162
40	Angiotensin IIâ€"Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer. JAMA Oncology, 2016, 2, 1030.	3.4	160
41	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. European Heart Journal, 2014, 35, 2165-2173.	1.0	159
42	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet, The, 2019, 394, 1254-1263.	6.3	159
43	Double-Blind Placebo-Controlled Study of Ibopamine and Diagoxin in Patients With Mild to Moderate Heart Failure: Results of the Dutch of the Ibopamine Multicenter Trial (DIMT). Journal of the American College of Cardiology, 1993, 22, 1564-1573.	1.2	158
44	A systems <scp>BIOlogy</scp> Study to <scp>TAilored</scp> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <scp>BIOSTATâ€CHF</scp>. European Journal of Heart Failure, 2016, 18, 716-726.	2.9	149
45	Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. International Journal of Cardiology, 2014, 174, 268-275.	0.8	147
46	Definition of Iron Deficiency Based on the Gold Standard of Bone Marrow Iron Staining in Heart Failure Patients. Circulation: Heart Failure, 2018, 11, e004519.	1.6	147
47	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. International Journal of Cardiology, 2018, 271, 132-139.	0.8	140
48	Effect of Metformin on Left Ventricular Function After Acute Myocardial Infarction in Patients Without Diabetes. JAMA - Journal of the American Medical Association, 2014, 311, 1526.	3.8	136
49	Identification of genomic loci associated with resting heart rate and shared genetic predictors with all-cause mortality. Nature Genetics, 2016, 48, 1557-1563.	9.4	131
50	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure, 2017, 5, 92-98.	1.9	129
51	Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials. American Heart Journal, 2014, 167, 853-860.e4.	1.2	128
52	Beta-Blockers and Outcome in Heart Failure and Atrial Fibrillation. JACC: Heart Failure, 2013, 1, 21-28.	1.9	123
53	Cancer and heart disease: associations and relations. European Journal of Heart Failure, 2019, 21, 1515-1525.	2.9	120
54	Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 of Heart Failure, 2009, 11, 1143-1151.	2.9	118

#	Article	IF	Citations
55	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. Circulation: Heart Failure, 2018, 11, e004962.	1.6	117
56	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With ReducedÂEjectionÂFraction. JACC: Heart Failure, 2022, 10, 73-84.	1.9	115
57	52 Genetic Loci Influencing MyocardialÂMass. Journal of the American College of Cardiology, 2016, 68, 1435-1448.	1.2	113
58	Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. Journal of Clinical Oncology, 2017, 35, 878-884.	0.8	113
59	Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE) Tj ETQq1 1 0.784314 rgBT /Overloc	6.3	112
60	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. European Heart Journal, 2020, 41, 3787-3797.	1.0	101
61	Effect of age and sex on efficacy and tolerability of Î² blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ, The, 2016, 353, i1855.	3.0	95
62	Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2018, 19, 425-432.	0.5	93
63	Presence and development of atrial fibrillation in chronic heart failure. European Journal of Heart Failure, 2006, 8, 539-546.	2.9	91
64	Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. European Heart Journal, 2022, 43, 1955-1969.	1.0	90
65	Echocardiographic estimation of left ventricular and pulmonary pressures in patients with heart failure and preserved ejection fraction: a study utilizing simultaneous echocardiography and invasive measurements. European Journal of Heart Failure, 2017, 19, 1651-1660.	2.9	89
66	Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a postâ€hoc analysis of the RACE II study. European Journal of Heart Failure, 2013, 15, 1311-1318.	2.9	88
67	The Use of Digoxin in Patients With Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1823-1832.	1.2	88
68	Tubular Damage and Worsening Renal Function in Chronic Heart Failure. JACC: Heart Failure, 2013, 1, 417-424.	1.9	87
69	Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure. Circulation: Heart Failure, 2021, 14, e007684.	1.6	87
70	Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations. Journal of the American College of Cardiology, 2016, 68, 1420-1431.	1.2	85
71	Waistâ€toâ€hip ratio and mortality in heart failure. European Journal of Heart Failure, 2018, 20, 1269-1277.	2.9	85
72	Selenium and outcome in heart failure. European Journal of Heart Failure, 2020, 22, 1415-1423.	2.9	84

#	Article	IF	Citations
73	Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure. European Heart Journal, 2016, 37, 2577-2585.	1.0	82
74	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245.	1.6	81
75	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	80
76	Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. European Journal of Heart Failure, 2021, 23, 68-78.	2.9	79
77	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from <scp>BIOSTATâ€CHF</scp>. European Journal of Heart Failure, 2017, 19, 1284-1293.	2.9	79
78	Biomarker Profiles of AcuteÂHeartÂFailureÂPatients With aÂMid-Range EjectionÂFraction. JACC: Heart Failure, 2017, 5, 507-517.	1.9	78
79	Health-Related Quality of Life in HeartÂFailure With Preserved EjectionÂFraction. JACC: Heart Failure, 2019, 7, 862-874.	1.9	77
80	Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort. Circulation: Heart Failure, 2014, 7, 723-731.	1.6	74
81	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. Heart, 2017, 103, 407-413.	1.2	74
82	Rationale and design of a randomized, doubleâ€blind, eventâ€driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the <scp>COMMANDER HF</scp> trial. European Journal of Heart Failure, 2015, 17, 735-742.	2.9	73
83	Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 983-991.	2.9	70
84	Optimizing clinical use of biomarkers in highâ€risk acute heart failure patients. European Journal of Heart Failure, 2016, 18, 269-280.	2.9	69
85	Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. European Heart Journal, 2019, 40, 3616-3625.	1.0	69
86	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal, 2019, 40, 3593-3602.	1.0	69
87	Association with outcomes and response to treatment of trimethylamine Nâ€oxide in heart failure: results from BIOSTATâ€CHF. European Journal of Heart Failure, 2019, 21, 877-886.	2.9	68
88	Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. Clinical Research in Cardiology, 2017, 106, 598-609.	1.5	66
89	Right Heart Dysfunction in Heart Failure With Preserved Ejection Fraction: The Impact of Atrial Fibrillation. Journal of Cardiac Failure, 2018, 24, 177-185.	0.7	65
90	Anemia in Heart Failure. JACC: Heart Failure, 2018, 6, 201-208.	1.9	65

#	Article	IF	Citations
91	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	1.0	65
92	Bioâ€adrenomedullin as a marker of congestion in patients with newâ€onset and worsening heart failure. European Journal of Heart Failure, 2019, 21, 732-743.	2.9	64
93	Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clinical Research in Cardiology, 2019, 108, 477-486.	1.5	64
94	Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study. Heart Rhythm, 2014, 11, 1543-1550.	0.3	62
95	Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.7	61
96	Fibrosis Marker Syndecan-1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. Circulation: Heart Failure, 2014, 7, 457-462.	1.6	60
97	Sexâ€specific associations of obesity and Nâ€terminal proâ€Bâ€type natriuretic peptide levels in the general population. European Journal of Heart Failure, 2018, 20, 1205-1214.	2.9	60
98	The additive burden of iron deficiency in the cardiorenalâ€“anaemia axis: scope of a problem and its consequences. European Journal of Heart Failure, 2014, 16, 655-662.	2.9	59
99	Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thrombosis Research, 2018, 169, 123-127.	0.8	59
100	The cardiopulmonary continuum systemic inflammation as â€˜common soilâ€™ of heart and lung disease. International Journal of Cardiology, 2010, 145, 172-176.	0.8	58
101	Potassium and the use of reninâ€“angiotensinâ€“aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTATâ€CHF. European Journal of Heart Failure, 2018, 20, 923-930.	2.9	57
102	Biomarkers and low risk in heart failure. Data from <scp>COACH</scp> and <scp>TRIUMPH</scp>. European Journal of Heart Failure, 2015, 17, 1271-1282.	2.9	55
103	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. International Journal of Cardiology, 2018, 253, 84-90.	0.8	55
104	Clinical importance of urinary sodium excretion in acute heart failure. European Journal of Heart Failure, 2020, 22, 1438-1447.	2.9	55
105	Iron deficiency and red cell indices in patients with heart failure. European Journal of Heart Failure, 2018, 20, 114-122.	2.9	54
106	Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. Circulation, 2022, 145, 1592-1604.	1.6	54
107	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. International Journal of Cardiology, 2016, 224, 231-239.	0.8	53
108	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. European Journal of Heart Failure, 2017, 19, 1310-1320.	2.9	53

#	Article	IF	Citations
109	Plasma interleukin 6 levels are associated with cardiac function after ST-elevation myocardial infarction. Clinical Research in Cardiology, 2019, 108, 612-621.	1.5	52
110	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. JAMA Cardiology, 2019, 4, 515.	3.0	51
111	Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and healthâ€related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. European Journal of Heart Failure, 2017, 19, 116-125.	2.9	50
112	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. European Journal of Heart Failure, 2020, 22, 1147-1155.	2.9	50
113	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2019, 20, 92-100.	0.5	48
114	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. European Heart Journal, 2018, 39, 3867-3875.	1.0	47
115	Genetic Determinants of P Wave Duration and PR Segment. Circulation: Cardiovascular Genetics, 2014, 7, 475-481.	5.1	45
116	Epicardial Adipose Tissue and Invasive Hemodynamics in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 667-676.	1.9	45
117	Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology. Journal of Clinical Medicine, 2022, 11, 125.	1.0	45
118	Dose response characterization of the association of serum digoxin concentration with mortality outcomes in the Digitalis Investigation Group trial. European Journal of Heart Failure, 2016, 18, 1072-1081.	2.9	44
119	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 112-120.	2.9	44
120	Renal Compression in HeartÂFailure. JACC: Heart Failure, 2022, 10, 175-183.	1.9	44
121	The PCSK9-LDL Receptor Axis andÂOutcomes in Heart Failure. Journal of the American College of Cardiology, 2017, 70, 2128-2136.	1.2	43
122	Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure. JAMA Cardiology, 2019, 4, 696.	3.0	43
123	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASISâ€HF trial. European Journal of Heart Failure, 2019, 21, 345-351.	2.9	43
124	Serial galectin-3 and future cardiovascular disease in the general population. Heart, 2016, 102, 1134-1141.	1.2	42
125	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. International Journal of Cardiology, 2017, 243, 360-366.	0.8	42
126	Right ventricular recovery after bilateral lung transplantation for pulmonary arterial hypertensionâ€. Interactive Cardiovascular and Thoracic Surgery, 2017, 24, 890-897.	0.5	42

#	Article	IF	Citations
127	The WAP Four-Disulfide Core Domain Protein HE4: A Novel Biomarker for Heart Failure. JACC: Heart Failure, 2013, 1, 164-169.	1.9	40
128	Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009238.	1.6	40
129	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq1 1 0.784314 rgBT /Overl	0.7	39
130	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. European Heart Journal, 2019, 40, 1287-1293.	1.0	39
131	Impact of Renal Impairment on Beta-Blocker Efficacy in PatientsÂWithÂHeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2893-2904.	1.2	39
132	Rationale and design of the CONFIRMâ€HF study: a doubleâ€blind, randomized, placeboâ€controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1, 52-58.	1.4	38
133	Erythropoietin in the General Population: Reference Ranges and Clinical, Biochemical and Genetic Correlates. PLoS ONE, 2015, 10, e0125215.	1.1	38
134	Serum ferritin and risk for newâ€onset heart failure and cardiovascular events in the community. European Journal of Heart Failure, 2017, 19, 348-356.	2.9	38
135	OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. Cardiovascular Research, 2018, 114, 1871-1882.	1.8	38
136	Telomere length and outcome in heart failure. Annals of Medicine, 2010, 42, 36-44.	1.5	37
137	Accumulation of 5-oxoproline in myocardial dysfunction and the protective effects of OPLAH. Science Translational Medicine, 2017, 9, .	5.8	36
138	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. European Journal of Heart Failure, 2015, 17, 1201-1207.	2.9	35
139	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	35
140	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. International Journal of Cardiology, 2016, 203, 564-569.	0.8	35
141	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. Journal of the American College of Cardiology, 2018, 71, 386-398.	1.2	35
142	Incidence and Outcomes of Pneumonia in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1961-1973.	1.2	35
143	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. International Journal of Cardiology, 2016, 204, 164-171.	0.8	34
144	Plasma biomarkers to predict or rule out early postâ€discharge events after hospitalization for acute heart failure. European Journal of Heart Failure, 2017, 19, 728-738.	2.9	34

#	Article	IF	Citations
145	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with midâ€range and preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1690-1697.	2.9	34
146	Clinical and Hemodynamic Correlates and Prognostic Value of VE/VCO 2 Slope in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension. Journal of Cardiac Failure, 2017, 23, 777-782.	0.7	34
147	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. European Journal of Heart Failure, 2017, 19, 792-799.	2.9	34
148	Pulmonary Valve Replacement: Twenty-Six Years of Experience With Mechanical Valvar Prostheses. Annals of Thoracic Surgery, 2015, 99, 905-910.	0.7	33
149	Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clinica Chimica Acta, 2016, 452, 50-57.	0.5	33
150	Clinical value of preâ€discharge bioâ€adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. European Journal of Heart Failure, 2020, 22, 683-691.	2.9	33
151	Serum uric acid, influence of sacubitrilâ€“valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: <scp>PARAGONâ€HF</scp>. European Journal of Heart Failure, 2020, 22, 2093-2101.	2.9	33
152	Neutrophilâ€toâ€lymphocyte ratio and outcomes in patients with newâ€onset or worsening heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 2021, 8, 3168-3179.	1.4	33
153	Plasma kidney injury moleculeâ€1 in heart failure: renal mechanisms and clinical outcome. European Journal of Heart Failure, 2016, 18, 641-649.	2.9	32
154	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology, 2016, 105, 145-153.	1.5	32
155	The year in cardiology 2018: heart failure. European Heart Journal, 2019, 40, 651-661.	1.0	32
156	Impact of mitral regurgitation in patients with worsening heart failure: insights from <scp>BIOSTATâ€CHF</scp>. European Journal of Heart Failure, 2021, 23, 1750-1758.	2.9	32
157	Rationale for and design of the <scp>TRUEâ€AHF</scp> trial: the effects of ularitide on the shortâ€term clinical course and longâ€term mortality of patients with acute heart failure. European Journal of Heart Failure, 2017, 19, 673-681.	2.9	31
158	Trajectory of self-care behaviour in patients with heart failure: the impact on clinical outcomes and influencing factors. European Journal of Cardiovascular Nursing, 2020, 19, 421-432.	0.4	31
159	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. European Heart Journal, 2015, 36, 2310-2317.	1.0	30
160	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 231-239.	0.7	30
161	Proteomic diversity of highâ€density lipoprotein explains its association with clinical outcome in patients with heart failure. European Journal of Heart Failure, 2018, 20, 260-267.	2.9	30
162	Epicardial fat in heart failure with reduced versus preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 835-838.	2.9	30

#	Article	IF	Citations
163	Diabetes and preâ€diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 497-509.	2.9	30
164	Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. Europace, 2014, 16, 1417-1425.	0.7	29
165	Bâ€type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure. European Journal of Heart Failure, 2019, 21, 1553-1560.	2.9	29
166	Right Ventricular Function After Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the Glycometabolic Intervention as Adjunct to Primary Percutaneous) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Cardiology, 2016, 118, 338-344.	0.7	28
167	The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure. Clinical Research in Cardiology, 2020, 109, 331-338.	1.5	28
168	Plasma proteomic approach in patients withÂheart failure: insights into pathogenesis ofÂdisease progression and potential novel treatment targets. European Journal of Heart Failure, 2020, 22, 70-80.	2.9	28
169	A network analysis to identify pathophysiological pathways distinguishing ischaemic from nonâ€ischaemic heart failure. European Journal of Heart Failure, 2020, 22, 821-833.	2.9	28
170	Cardiac function and cardiac events 1-year postpartum in women with congenital heart disease. American Heart Journal, 2015, 169, 298-304.	1.2	27
171	Cardiac adaption during pregnancy in women with congenital heart disease and healthy women. Heart, 2016, 102, 1302-1308.	1.2	27
172	The importance of myocardial contractile reserve in predicting response to cardiac resynchronization therapy. European Journal of Heart Failure, 2017, 19, 862-869.	2.9	27
173	Vitamin B12and folate deficiency in chronic heart failure. Heart, 2015, 101, 302-310.	1.2	26
174	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. Circulation: Heart Failure, 2018, 11, e004926.	1.6	26
175	Hyperkalemia and Treatment With RAASÂInhibitors During Acute HeartÂFailure Hospitalizations and TheirÂAssociation With Mortality. JACC: Heart Failure, 2019, 7, 970-979.	1.9	26
176	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. European Journal of Heart Failure, 2021, 23, 567-577.	2.9	26
177	Natriuresisâ€guided therapy in acute heart failure: rationale and design of the <scp>Pragmatic Urinary Sodiumâ€based treatment algoritHm</scp> in <scp>Acute Heart Failure</scp> (<scp>PUSHâ€AHF</scp>) trial. European Journal of Heart Failure, 2022, 24, 385-392.	2.9	26
178	Clinical correlates and outcome associated with changes in 6â€minute walking distance in patients with heart failure: findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2019, 21, 218-226.	2.9	25
179	Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the <scp>VIPâ€HF</scp> study. European Journal of Heart Failure, 2020, 22, 1923-1929.	2.9	25
180	Distinct Pathological Pathways in Patients With HeartÂFailure and Diabetes. JACC: Heart Failure, 2020, 8, 234-242.	1.9	25

#	Article	IF	Citations
181	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	1.6	25
182	Thirst Trajectory and Factors Associated With Persistent Thirst in Patients With Heart Failure. Journal of Cardiac Failure, 2014, 20, 689-695.	0.7	24
183	Twenty-eight genetic loci associated with ST-T-wave amplitudes of the electrocardiogram. Human Molecular Genetics, 2016, 25, 2093-2103.	1.4	24
184	The contemporary value of peak creatine kinaseâ€‹<scp>MB</scp> after <scp>ST</scp>â€‹segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality. Clinical Cardiology, 2017, 40, 322-328.	0.7	24
185	Pregnancy in women with pre-existent ischaemic heart disease: a systematic review with individualised patient data. Heart, 2019, 105, 873-880.	1.2	24
186	The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. European Journal of Heart Failure, 2020, 22, 2102-2111.	2.9	24
187	Effects of combined reninâ€“angiotensinâ€“aldosterone system inhibitor and betaâ€blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <scp>BIOSTATâ€CHF</scp> and <scp>ASIANâ€HF</scp> registries. European Journal of Heart Failure, 2020, 22, 1472-1482.	2.9	24
188	Effect of Right Ventricular Outflow Tract Obstruction on Right Ventricular Volumes and Exercise Capacity in Patients With Repaired Tetralogy of Fallot. American Journal of Cardiology, 2014, 113, 719-723.	0.7	23
189	The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial. BMJ Open Diabetes Research and Care, 2015, 3, e000090.	1.2	23
190	Effect of Systolic Blood Pressure on Left Ventricular Structure and Function. Hypertension, 2019, 74, 826-832.	1.3	23
191	Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). Journal of Cardiac Failure, 2019, 25, 654-665.	0.7	23
192	Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. Circulation: Heart Failure, 2019, 12, e005544.	1.6	23
193	The bidirectional interaction between atrial fibrillation and heart failure: consequences for the management of both diseases. Europace, 2021, 23, ii40-ii45.	0.7	23
194	Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?. Journal of Internal Medicine, 2022, 291, 713-731.	2.7	23
195	Two-year follow-up of 4Âmonths metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT. Clinical Research in Cardiology, 2017, 106, 939-946.	1.5	22
196	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. American Journal of Cardiology, 2018, 121, 107-112.	0.7	22
197	Bucindolol for the Maintenance of SinusÂRhythm in a Genotype-Defined HFÂPopulation. JACC: Heart Failure, 2019, 7, 586-598.	1.9	22
198	Sex-related differences in risk factors, outcome, and quality of life in patients with permanent atrial fibrillation: results from the RACE II study. Europace, 2020, 22, 1619-1627.	0.7	22

#	Article	IF	Citations
199	Importance of epicardial adipose tissue localization using cardiac magnetic resonance imaging in patients with heart failure with midâ€range and preserved ejection fraction. Clinical Cardiology, 2021, 44, 987-993.	0.7	22
200	Integrating High-Sensitivity Troponin T andÂSacubitril/Valsartan Treatment inÂHFpEF. JACC: Heart Failure, 2021, 9, 627-635.	1.9	21
201	Association of Circulating Ketone BodiesÂWith Functional Outcomes AfterÂST-Segment Elevation MyocardialÂInfarction. Journal of the American College of Cardiology, 2021, 78, 1421-1432.	1.2	21
202	Relative fat mass, a new index of adiposity, is strongly associated with incident heart failure: data from PREVEND. Scientific Reports, 2022, 12, 147.	1.6	21
203	Predictors of left ventricular remodeling after ST-elevation myocardial infarction. International Journal of Cardiovascular Imaging, 2017, 33, 1415-1423.	0.7	20
204	Heart failure treatment upâ€ŧitration and outcome and age: an analysis of BIOSTATâ€ŒCHF. European Journal of Heart Failure, 2021, 23, 436-444.	2.9	20
205	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2020, 109, 1048-1059.	1.5	20
206	Additional burden of iron deficiency in heart failure patients beyond the cardioâ€renal anaemia syndrome: findings from the <scp>BIOSTATâ€ŒCHF</scp> study. European Journal of Heart Failure, 2022, 24, 192-204.	2.9	20
207	Pregnancy in women with corrected aortic coarctation: Uteroplacental Doppler flow and pregnancy outcome. International Journal of Cardiology, 2017, 249, 145-150.	0.8	19
208	Targeted therapy of underlying conditions improves quality of life in patients with persistent atrial fibrillation: results of the RACE 3 study. Europace, 2019, 21, 563-571.	0.7	19
209	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. European Journal of Heart Failure, 2020, 22, 1402-1411.	2.9	19
210	Shortâ€term prognostic implications of serum and urine neutrophil gelatinaseâ€associated lipocalin in acute heart failure: findings from the AKINESIS study. European Journal of Heart Failure, 2020, 22, 251-263.	2.9	19
211	Is acute heart failure a distinctive disorder? An analysis from BIOSTATâ€ŒCHF. European Journal of Heart Failure, 2021, 23, 43-57.	2.9	19
212	Hemoglobin levels and new-onset heart failure in the community. American Heart Journal, 2015, 169, 94-101.e2.	1.2	18
213	Validity and Predictive Value of a Portable Two-Channel Sleep-Screening Tool in the Identification of Sleep Apnea inÂPatients With Heart Failure. Journal of Cardiac Failure, 2015, 21, 848-855.	0.7	17
214	Chronic ischemic mitral regurgitation and papillary muscle infarction detected by late gadolinium-enhanced cardiac magnetic resonance imaging in patients with ST-segment elevation myocardial infarction. Clinical Research in Cardiology, 2016, 105, 981-991.	1.5	17
215	Long-term changes in renal function and perfusion in heart failure patients with reduced ejection fraction. Clinical Research in Cardiology, 2016, 105, 10-16.	1.5	17
216	High-sensitivity C-reactive protein and long term reperfusion success of primary percutaneous intervention in ST-elevation myocardial infarction. International Journal of Cardiology, 2017, 248, 51-56.	0.8	17

#	Article	IF	Citations
217	Relationship between body mass index, cardiovascular biomarkers and incident heart failure. European Journal of Heart Failure, 2021, 23, 396-402.	2.9	17
218	Effect of additive renin inhibition with aliskiren on renal blood flow in patients with Chronic Heart Failure and Renal Dysfunction (Additive Renin Inhibition with Aliskiren on renal blood flow and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 Heart Journal, 2015, 169, 693-701.e3.	1.2	16
219	Effect of Metformin on Metabolites and Relation With Myocardial Infarct Size and Left Ventricular Ejection Fraction After Myocardial Infarction. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	16
220	Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythmâ€"A <scp>CIBIS II</scp> analysis. Clinical Cardiology, 2017, 40, 740-745.	0.7	16
221	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. Heart, 2018, 104, 606-613.	1.2	16
222	Biological versus mechanical heart valve prosthesis during pregnancy in women with congenital heart disease. International Journal of Cardiology, 2018, 268, 106-112.	0.8	16
223	Genetic risk and atrial fibrillation in patients with heart failure. European Journal of Heart Failure, 2020, 22, 519-527.	2.9	15
224	Cardiovascular and nonâ€cardiovascular death distinction: the utility of troponin beyond Nâ€terminal proâ€Bâ€type natriuretic peptide. Findings from the BIOSTATâ€CHF study. European Journal of Heart Failure, 2020, 22, 81-89.	2.9	15
225	The value of spot urinary creatinine as a marker of muscle wasting in patients with newâ€onset or worsening heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 555-567.	2.9	15
226	Nonâ€adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatographyâ€tandem mass spectrometry (results of a prospective) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 377	2.9	15
227	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. European Journal of Heart Failure, 2022, 24, 821-832.	2.9	15
228	Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction. American Journal of Cardiology, 2018, 121, 621-627.	0.7	14
229	Natriuretic Peptide-Based Inclusion Criteria in a HeartÂFailure Clinical Trial. JACC: Heart Failure, 2020, 8, 359-368.	1.9	14
230	Decongestion discriminates risk for oneâ€year mortality in patients with improving renal function in acute heart failure. European Journal of Heart Failure, 2021, 23, 1122-1130.	2.9	14
231	Ischemia and Left Ventricular Dysfunction: A Reciprocal Relation?. Journal of Cardiovascular Pharmacology, 1998, 32, S46-S51.	0.8	14
232	High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND. European Journal of Heart Failure, 2016, 18, 814-821.	2.9	13
233	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). Circulation: Heart Failure, 2018, 11, e004431.	1.6	13
234	Plasma <scp>D</scp>â€dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the <scp>COMMANDERâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 648-656.	2.9	13

#	Article	IF	Citations
235	Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction. ESC Heart Failure, 2021, 8, 2458-2466.	1.4	13
236	Effect of Metformin Treatment on Lipoprotein Subfractions in Non-Diabetic Patients with Acute Myocardial Infarction: A Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) Trial. PLoS ONE, 2016, 11, e0145719.	1.1	13
237	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGONâ€HF. Journal of the American Heart Association, 2021, 10, e021494.	1.6	13
238	Alterations in the prognosis of chronic heart failure: an overview of the major mortality trials. Cardiovascular Drugs and Therapy, 1997, 11, 427-434.	1.3	12
239	New developments in the pharmacotherapeutic management of heart failure in elderly patients: concerns and considerations. Expert Opinion on Pharmacotherapy, 2017, 18, 645-655.	0.9	12
240	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. European Journal of Internal Medicine, 2020, 71, 62-69.	1.0	12
241	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. Journal of Hypertension, 2020, 38, 420-425.	0.3	12
242	Safety and Tolerability of Sodium Thiosulfate in Patients with an Acute Coronary Syndrome Undergoing Coronary Angiography: A Dose-Escalation Safety Pilot Study (SAFE-ACS). Journal of Interventional Cardiology, 2020, 2020, 1-8.	0.5	12
243	Surviving the first <scp>COVID</scp>â€19 wave and learning lessons for the second. European Journal of Heart Failure, 2020, 22, 975-977.	2.9	12
244	Serum potassium and outcomes in heart failure with preserved ejection fraction: a postâ€hoc analysis of the <scp>PARAGONâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 776-784.	2.9	12
245	Rationale and Design of the Groningen Intervention Study for the Preservation of Cardiac Function with Sodium Thiosulfate after St-segment Elevation Myocardial Infarction (GIPS-IV) trial. American Heart Journal, 2022, 243, 167-176.	1.2	12
246	The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. PLoS ONE, 2016, 11, e0168340.	1.1	12
247	Acute heart failure in the young: Clinical characteristics and biomarker profiles. International Journal of Cardiology, 2016, 221, 1067-1072.	0.8	11
248	Cardiotoxicity of breast cancer treatment: no easy solution for an important long-term problem. European Heart Journal, 2016, 37, 1681-1683.	1.0	11
249	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. Circulation: Heart Failure, 2017, 10, .	1.6	11
250	Potential Utility of Cardiorenal Biomarkers for Prediction and Prognostication of Worsening Renal Function in Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 533-541.	0.7	11
251	Antiarrhythmic drugs in patients with early persistent atrial fibrillation and heart failure: results of the RACE 3 study. Europace, 2021, 23, 1359-1368.	0.7	11
252	Association between upâ€titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181.	2.9	11

#	Article	IF	Citations
253	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. European Journal of Heart Failure, 2021, 23, 1677-1686.	2.9	11
254	Autonomic and hemodynamic effects of a new selective dopamine agonist, CHF1035, in patients with chronic heart failure. Cardiovascular Drugs and Therapy, 2001, 15, 139-145.	1.3	10
255	Vitamin D supplementation in heart failure: case closed?. European Heart Journal, 2017, 38, 2287-2289.	1.0	10
256	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clinical Research in Cardiology, 2019, 108, 797-805.	1.5	10
257	High-Sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences Between Women and Men. Mayo Clinic Proceedings, 2020, 95, 1158-1168.	1.4	10
258	What should the C (â€˜congestive heart failureâ€™) represent in the <scp>CHA₂DS₂â€VASc</scp> score?. European Journal of Heart Failure, 2020, 22, 1294-1297.	2.9	10
259	The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. Pflugers Archiv European Journal of Physiology, 2021, 473, 1301-1313.	1.3	10
260	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. Cardiovascular Research, 2022, 118, 1964-1977.	1.8	10
261	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clinical Research in Cardiology, 2022, 111, 912-923.	1.5	10
262	The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis: association analysis in the COntrolled ROsuvastatin multiNAtional trial in heart failure (CORONA). BMC Medical Genetics, 2014, 15, 140.	2.1	9
263	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. American Heart Journal, 2018, 199, 51-58.	1.2	9
264	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. ESC Heart Failure, 2020, 7, 953-963.	1.4	9
265	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the reninâ€“angiotensinâ€“aldosterone system in patients with heart failure. European Journal of Heart Failure, 2021, 23, 947-953.	2.9	9
266	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. European Journal of Heart Failure, 2022, 24, 308-320.	2.9	9
267	The value of echocardiographic measurement of epicardial adipose tissue in heart failure patients. ESC Heart Failure, 2022, 9, 953-957.	1.4	9
268	Letter from the incoming Editorâ€inâ€Chief of the European Journal of Heart Failure. European Journal of Heart Failure, 2010, 12, 1-2.	2.9	8
269	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. Cardiovascular Drugs and Therapy, 2017, 31, 281-293.	1.3	8
270	Nâ€terminal proâ€Bâ€type natriuretic peptide and prognosis in <scp>Caucasian</scp> vs. <scp>Asian</scp> patients with heart failure. ESC Heart Failure, 2018, 5, 279-287.	1.4	8

#	Article	IF	Citations
271	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. Cardiovascular Research, 2021, 117, 2228-2236.	1.8	8
272	Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation â€“ Data from RACE 3. American Heart Journal, 2020, 226, 235-239.	1.2	8
273	The clinical and prognostic value of late Gadolinium enhancement imaging in heart failure with mid-range and preserved ejection fraction. Heart and Vessels, 2022, 37, 273-281.	0.5	8
274	Responder analysis for improvement in sixâ€minute walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. European Journal of Heart Failure, 2022, , .	2.9	8
275	Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure. European Journal of Heart Failure, 2022, 24, 2131-2139.	2.9	8
276	Right ventricular dysfunction in heart failure with reduced vs. preserved ejection fraction: nonâ€identical twins?. European Journal of Heart Failure, 2017, 19, 880-882.	2.9	7
277	Residual confounding in observational studies: new data from the old DIG trial. European Heart Journal, 2019, 40, 3342-3344.	1.0	7
278	New data on soluble ACE2 in patients with atrial fibrillation reveal potential value for treatment of patients with COVID-19 and cardiovascular disease. European Heart Journal, 2020, 41, 4047-4049.	1.0	7
279	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. Clinical Research in Cardiology, 2020, 109, 967-977.	1.5	7
280	Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. American Journal of Cardiology, 2021, 147, 70-79.	0.7	7
281	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. Journal of Cardiac Failure, 2021, 27, 808-811.	0.7	7
282	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <scp>EMPHASISâ€HF</scp> and <scp>RALES</scp>. European Journal of Heart Failure, 2022, 24, 529-538.	2.9	7
283	Cardiovascular determinants of impaired placental function in women with cardiac dysfunction. American Heart Journal, 2022, 245, 126-135.	1.2	7
284	Clinical implications of low estimated protein intake in patients with heart failure. Journal of Cachexia, Sarcopenia and Muscle, 2022, , .	2.9	7
285	Leukocyte telomere length and left ventricular function after acute ST-elevation myocardial infarction: data from the glycometabolic intervention as adjunct to primary coronary intervention in ST elevation myocardial infarction (GIPS-III) trial. Clinical Research in Cardiology, 2015, 104, 812-821.	1.5	6
286	Value of digoxin in patients with heart failure: new pieces to the puzzle. European Journal of Heart Failure, 2018, 20, 1146-1147.	2.9	6
287	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical Proteomics, 2018, 15, 35.	1.1	6
288	T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. Clinical Research in Cardiology, 2019, 108, 133-141.	1.5	6

#	Article	IF	Citations
289	Impact of Geographic Region on the COMMANDER-HF Trial. JACC: Heart Failure, 2021, 9, 201-211.	1.9	6
290	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. Clinical Research in Cardiology, 2022, 111, 50-59.	1.5	6
291	Decongestion, kidney injury and prognosis in patients with acute heart failure. International Journal of Cardiology, 2022, 354, 29-37.	0.8	6
292	A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?. European Heart Journal, 2022, 43, 2221-2223.	1.0	6
293	Whole blood transcriptomic profiling identifies molecular pathways related to cardiovascular mortality in heart failure. European Journal of Heart Failure, 2022, 24, 1009-1019.	2.9	6
294	Heart Failure and Pancreas Exocrine Insufficiency: Pathophysiological Mechanisms and Clinical Point of View. Journal of Clinical Medicine, 2022, 11, 4128.	1.0	6
295	Safety and clinical outcome of erythropoiesis-stimulating agents in patients with ST-elevation myocardial infarction: A meta-analysis of individual patient data. American Heart Journal, 2014, 168, 354-362.e2.	1.2	5
296	Ischaemia in heart failure with preserved ejection fraction; is it important?. European Journal of Heart Failure, 2016, 18, 577-578.	2.9	5
297	Measuring Pulmonary Artery Pressures in Heart Failure. Circulation, 2017, 135, 1518-1521.	1.6	5
298	Doppler gradients, valve area and ventricular function in pregnant women with aortic or pulmonary valve disease: Left versus right. International Journal of Cardiology, 2020, 306, 152-157.	0.8	5
299	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHESUS, and EXAMINE. Clinical Research in Cardiology, 2021, 110, 1554-1563.	1.5	5
300	Telomere length is independently associated with all-cause mortality in chronic heart failure. Heart, 2022, 108, 124-129.	1.2	5
301	Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovascular Research, 2022, 118, 2478-2487.	1.8	5
302	Surrogate markers of gut dysfunction are related to heart failure severity and outcomeâ€“from the BIOSTAT-CHF consortium. American Heart Journal, 2022, 248, 108-119.	1.2	5
303	Agreement of 2D transthoracic echocardiography with cardiovascular magnetic resonance imaging after ST-elevation myocardial infarction. European Journal of Radiology, 2019, 114, 6-13.	1.2	4
304	Rapid right-sided deterioration in heart failure with preserved ejection fraction. European Heart Journal, 2019, 40, 699-702.	1.0	4
305	Myocardial adiposity in heart failure with preserved ejection fraction: the plot thickens. European Journal of Heart Failure, 2020, 22, 455-457.	2.9	4
306	Reduced right ventricular function on cardiovascular magnetic resonance imaging is associated with uteroplacental impairment in tetralogy of Fallot. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 52.	1.6	4

#	Article	IF	Citations
307	Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction. Cardiovascular Drugs and Therapy, 2020, 35, 953-963.	1.3	4
308	Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. Europace, 2022, 24, 910-920.	0.7	4
309	Dapagliflozin effect on heart failure with prevalent or newâ€onset atrial fibrillation. European Journal of Heart Failure, 2022, 24, 526-528.	2.9	4
310	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 228-239.	2.2	4
311	Biomarker changes as surrogate endpoints in earlyâ€phase trials in heart failure with reduced ejection fraction. ESC Heart Failure, 2022, 9, 2107-2118.	1.4	4
312	Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia. Expert Opinion on Pharmacotherapy, 2016, 17, 1527-1538.	0.9	3
313	Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). Cardiovascular Pathology, 2017, 29, 19-22.	0.7	3
314	Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. European Journal of Heart Failure, 2020, 22, 903-906.	2.9	3
315	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure. Clinical Cardiology, 2021, 44, 780-788.	0.7	3
316	Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. Clinical Research in Cardiology, 2021, 110, 1308-1320.	1.5	3
317	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. Circulation: Heart Failure, 2021, 14, e008075.	1.6	3
318	Patients with heart failure with and without a history of stroke in the Netherlands: a secondary analysis of psychosocial, behavioural and clinical outcomes up to three years from the COACH trial. BMJ Open, 2019, 9, e025525.	0.8	2
319	Six-minute walk test: prognostic value and effects of nebivolol versus placebo in elderly patients with heart failure from the SENIORS trial. Clinical Research in Cardiology, 2021, 110, 1193-1201.	1.5	2
320	Sudden cardiac death in heart failure: more than meets the eye. European Journal of Heart Failure, 2021, 23, 1361-1363.	2.9	2
321	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. Cardiac Failure Review, 2020, 6, e21.	1.2	2
322	Sex differences in associations of comorbidities with incident cardiovascular disease: focus on absolute risk. European Heart Journal Open, 2022, 2, .	0.9	2
323	Response to Letter Regarding Article, â€œRenal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failureâ€. Circulation, 2006, 114, .	1.6	1
324	Prescription of betaâ€blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. European Journal of Heart Failure, 2007, 9, 962-963.	2.9	1

#	Article	IF	Citations
325	The European Journal of Heart Failure from 2010 to 2015. European Journal of Heart Failure, 2014, 16, 1259-1262.	2.9	1
326	Data Sharing From the Editors' Perspective. JACC: Heart Failure, 2017, 5, 314-315.	1.9	1
327	Causal Pathways from Blood Pressure to Larger QRS Amplitudes: a Mendelian Randomization Study. Scientific Reports, 2018, 8, 5817.	1.6	1
328	Proâ€gastrinâ€releasing peptide and outcome in patients with heart failure and anaemia: results from the REDâ€HF study. ESC Heart Failure, 2018, 5, 1052-1059.	1.4	1
329	Discussion forum response to Canepa et al. European Heart Journal, 2019, 40, 705-706.	1.0	1
330	Rightâ€sided cardiac disease: no longer the â€˜dark side of the heartâ€™. European Journal of Heart Failure, 2020, 22, 1226-1229.	2.9	1
331	Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients. Surgery for Obesity and Related Diseases, 2021, 17, 64-71.	1.0	1
332	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1, n/a-n/a.	1.4	1
333	1370: The impact of depressive symptoms and quality of life in HF patients compared with community dwelling elderly. European Journal of Cardiovascular Nursing, 2007, 6, 40-40.	0.4	0
334	1325 Severity of depressive symptoms is related to hospital admission in patients with heart failure. European Journal of Cardiovascular Nursing, 2008, 7, 15-16.	0.4	0
335	Response to Letter Regarding Article, â€œEndogenous Erythropoietin and Outcome in Heart Failureâ€. Circulation, 2010, 122, .	1.6	0
336	Atrial fibrillation is more troublesome in heart failure patients with preserved compared to those with reduced ejection fraction. International Journal of Cardiology, 2018, 266, 155-156.	0.8	0
337	Heart rate in patients with atrial fibrillation and heart failure with preserved ejection fraction: a prognosticator like in sinus rhythm?. European Journal of Heart Failure, 2019, 21, 480-481.	2.9	0
338	Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial.. Journal of Clinical Oncology, 2013, 31, 525-525.	0.8	0
339	Dose Limiting, Adverse Event Associated Bradycardia with Î²-blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial. Heart Rhythm O2, 2021, 3, 40-49.	0.6	0
340	Underestimation of congestion in very obese heart failure with preserved ejection fraction patients: <scp>EAT</scp> your heart outâ€¦?!. European Journal of Heart Failure, 2022, 24, 362-364.	2.9	0
341	128â€ƒClinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. European Heart Journal Supplements, 2021, 23, .	0.0	0